IMC Chicago’s Pacific Biosciences PACB Stock Holding History

IMC Chicago’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$47.4K	Buy	+35,900	New	+$64.2K	﹤0.01%	5528
2024 Q2	–	Sell	-124,500	Closed	-$467K	–	2741
2024 Q1	$467K	Buy	+124,500	New	+$729K	﹤0.01%	2071

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

IMC Chicago's PACB Position: Q2 2024 in Review

IMC Chicago sold out of Pacific Biosciences (PACB) in Q2 2024, closing a stake of 115,620 shares — an estimated $434K sold.

IMC Chicago first reported a position in PACB in Q1 2024 and held it in 1 quarter. The position peaked at $434K in Q1 2024. 228 funds tracked by Wall St. Rank hold PACB as of Q2 2024.

IMC Chicago reported no remaining Pacific Biosciences position as of Q2 2024 after selling out during the quarter.
IMC Chicago sold 115,620 Pacific Biosciences shares in Q2 2024, an estimated $434K.
IMC Chicago first reported a position in Pacific Biosciences in Q1 2024 and held it in 1 quarter.
IMC Chicago's Pacific Biosciences position peaked at $434K in Q1 2024.
228 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2024.

Based on IMC Chicago's 13F filing for Q2 2024, filed 15 Jul 2024.